Metropolitan Life Insurance Co. NY lowered its position in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 6.7% during the first quarter, Holdings Channel reports. The fund owned 19,401 shares of the biotechnology company’s stock after selling 1,395 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Aimmune Therapeutics were worth $422,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Teachers Advisors LLC boosted its position in Aimmune Therapeutics by 2.4% in the fourth quarter. Teachers Advisors LLC now owns 43,229 shares of the biotechnology company’s stock worth $884,000 after buying an additional 1,025 shares in the last quarter. American International Group Inc. boosted its position in Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after buying an additional 1,070 shares in the last quarter. Nationwide Fund Advisors boosted its position in Aimmune Therapeutics by 23.7% in the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock worth $437,000 after buying an additional 3,851 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Aimmune Therapeutics by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company’s stock worth $1,892,000 after buying an additional 4,788 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock worth $130,000 after buying an additional 4,900 shares in the last quarter. Institutional investors and hedge funds own 69.65% of the company’s stock.

Aimmune Therapeutics, Inc. (NASDAQ AIMT) traded up 0.62% during trading on Wednesday, reaching $19.43. The company’s stock had a trading volume of 16,530 shares. The stock’s 50-day moving average is $20.90 and its 200 day moving average is $20.00. The firm’s market capitalization is $981.90 million. Aimmune Therapeutics, Inc. has a 52-week low of $12.38 and a 52-week high of $27.31.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.01. On average, analysts predict that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/metropolitan-life-insurance-co-ny-cuts-stake-in-aimmune-therapeutics-inc-aimt/1494930.html.

A number of equities analysts have weighed in on AIMT shares. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “buy” rating and set a $21.00 price target for the company in a report on Tuesday, May 16th. ValuEngine cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 27th. Piper Jaffray Companies set a $38.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, July 27th. Wedbush restated an “outperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a report on Monday, July 24th. Finally, BidaskClub cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Aimmune Therapeutics has a consensus rating of “Hold” and a consensus price target of $33.00.

In other Aimmune Therapeutics news, insider Susan E. Barrowcliffe sold 6,110 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $22.00, for a total value of $134,420.00. Following the sale, the insider now owns 960 shares of the company’s stock, valued at approximately $21,120. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen George Dilly sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $21.46, for a total value of $1,073,000.00. The disclosure for this sale can be found here. Insiders sold a total of 188,470 shares of company stock worth $3,942,092 in the last ninety days. Insiders own 24.56% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics, Inc. (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.